We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Anticorps anti-VEGF: un emploi universel?
- Authors
Ray-Coquard, I.; Bachelot, T.; Saba, C.; Confavreux, C.; Brantus, J.-F.; Rustam, F.; Gesquière, H.; Sebban, C.; Biron, P.; Guastalla, J.-P.; Blay, J.-Y.
- Abstract
After over 30 years of theory, the use of angiogenesis inhibitors for anticancer therapy has finally moved from the realm of research to reality. Normal adult vasculature is generally quiescent in nature, with endothelial cells dividing approximately every 10 years. In contrast, tumour growth requires constant vascularization and remodelling in order for solid tumours to grow beyond 1-2 mm3 in size. Vascular endothelial growth factor (VEGF) and its receptors are key regulators of the process of angiogenesis, which makes them attractive therapeutic targets. A multitude of VEGF-targeted inhibitory agents are currently being investigated for the treatment of cancer. This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers.
- Subjects
NEOVASCULARIZATION; LUNG cancer; BREAST cancer; COLON cancer; VASCULAR endothelial growth factors; GROWTH factors; THERAPEUTICS
- Publication
Oncologie (Tech Science Press), 2006, Vol 8, Issue 9, p808
- ISSN
1292-3818
- Publication type
Article
- DOI
10.1007/s10269-006-0520-1